HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flotte, T. R. Articles by Laube, B. L. Search for Related Content PubMed PubMed Citation Articles by Flotte, T. R. Articles by Laube, B. L.

Gene Therapy in Cystic Fibrosis^*

^* From the Powell Gene Therapy Center of the University of Florida Genetics Institute, Gainesville, FL (Dr. Flotte); and the Johns Hopkins University, Baltimore, MD.

Correspondence to: Terence R. Flotte, MD, Box 100266 JHMHSC, Gainesville, FL 32610-0266; e-mail: flotttr{at}peds.ufl.edu

Theoretically, cystic fibrosis transmembrane conductance regulator (CFTR) gene replacement during the neonatal period can decrease morbidity and mortality from cystic fibrosis (CF). In vivo gene transfers have been accomplished in CF patients. Choice of vector, mode of delivery to airways, translocation of genetic information, and sufficient expression level of the normalized CFTR gene are issues that currently are being addressed in the field. The advantages and limitations of viral vectors are a function of the parent virus. Viral vectors used in this setting include adenovirus (Ad) and adeno-associated virus (AAV). Initial studies with Ad vectors resulted in a vector that was efficient for gene transfer with dose-limiting inflammatory effects due to the large amount of viral protein delivered. The next generation of Ad vectors, with more viral coding sequence deletions, has a longer duration of activity and elicits a lesser degree of cell-mediated immunity in mice. A more recent generation of Ad vectors has no viral genes remaining. Despite these changes, the problem of humoral immunity remains with Ad vectors. A variety of strategies such as vector systems requiring single, or widely spaced, administrations, pharmacologic immunosuppression at administration, creation of a stealth vector, modification of immunogenic epitopes, or tolerance induction are being considered to circumvent humoral immunity. AAV vectors have been studied in animal and human models. They do not appear to induce inflammatory changes over a wide range of doses. The level of CFTR messenger RNA expression is difficult to ascertain with AAV vectors since the small size of the vector relative to the CFTR gene leaves no space for vector-specific sequences on which to base assays to distinguish endogenous from vector-expressed messenger RNA. In general, AAV vectors appear to be safe and have superior duration profiles. Cationic liposomes are lipid-DNA complexes. These vectors generally have been less efficient than viral vectors but do not stimulate inflammatory and immunologic responses. Another challenge to the development of clinically feasible gene therapy is delivery mode. Early pulmonary delivery systems relied on the direct instillation of aerosolized vectors, which can result in the induction of adverse reactions because vector is delivered into the lung parenchyma. More recent studies have examined the potential for using spray technologies to target aerosolized AAV vectors to the larger central airways, thereby avoiding alveolar exposure and adverse effects. Comparisons of lung deposition with nebulized delivery of aerosol and spray delivery indicate that spraying results in a more localized deposition pattern (predominantly in the proximal airways) and significantly higher deposition fractions than nebulization. These findings could lead to more efficient and targeted lung delivery of aerosolized gene vectors in the future.

Key Words: adeno-associated virus • adenovirus • cationic liposome • cystic fibrosis transmembrane conductance regulator • Escherichia coli • lipoplex • microsprayer • natural killer cells • nebulizer • neutrophil-mediated inflammatory response • Pseudomonas aeruginosa • rhesus macaque monkeys • transfection • viral protein • viral vector

This article has been cited by other articles:

				M. P. Limberis and J. M. Wilson Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered PNAS, August 29, 2006; 103(35): 12993 - 12998. [Abstract] [Full Text] [PDF]

				A. E. Arbetman, M. Lochrie, S. Zhou, J. Wellman, C. Scallan, M. M. Doroudchi, B. Randlev, S. Patarroyo-White, T. Liu, P. Smith, et al. Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties J. Virol., December 15, 2005; 79(24): 15238 - 15245. [Abstract] [Full Text] [PDF]

				S. L. Farmen, P. H. Karp, P. Ng, D. J. Palmer, D. R. Koehler, J. Hu, A. L. Beaudet, J. Zabner, and M. J. Welsh Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR Am J Physiol Lung Cell Mol Physiol, December 1, 2005; 289(6): L1123 - L1130. [Abstract] [Full Text] [PDF]

				S. Grossman and L. C. Grossman Pathophysiology of Cystic Fibrosis: Implications for Critical Care Nurses Crit. Care Nurse, August 1, 2005; 25(4): 46 - 51. [Full Text] [PDF]

				J. H. Thrall Personalized Medicine Radiology, June 1, 2004; 231(3): 613 - 616. [Full Text] [PDF]

				R. B. Moss, D. Rodman, L. T. Spencer, M. L. Aitken, P. L. Zeitlin, D. Waltz, C. Milla, A. S. Brody, J. P. Clancy, B. Ramsey, et al. Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial Chest, February 1, 2004; 125(2): 509 - 521. [Abstract] [Full Text] [PDF]

				J. Zhou, Y. You, J. Zabner, A. J. Ryan, and R. K. Mallampalli The CCT Promoter Directs High-Level Transgene Expression in Distal Lung Epithelial Cell Lines Am. J. Respir. Cell Mol. Biol., January 1, 2004; 30(1): 61 - 68. [Abstract] [Full Text] [PDF]

				C. Qiao, B. Wang, X. Zhu, J. Li, and X. Xiao A Novel Gene Expression Control System and Its Use in Stable, High-Titer 293 Cell-Based Adeno-Associated Virus Packaging Cell Lines J. Virol., November 13, 2002; 76(24): 13015 - 13027. [Abstract] [Full Text] [PDF]

				A. SAARISTO, T. VEIKKOLA, B. ENHOLM, M. HYTONEN, J. AROLA, K. PAJUSOLA, P. TURUNEN, M. JELTSCH, M. J. KARKKAINEN, D. KERJASCHKI, et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes FASEB J, July 1, 2002; 16(9): 1041 - 1049. [Abstract] [Full Text] [PDF]